Difficulties in the diagnosis and management of eight infants with secondary pseudohypoaldosteronism

Fatih Günay¹, Zeynep Şıklar², Merih Berberoğlu²

¹Division of Pediatric Endocrinology, ²Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey.

ABSTRACT

Background. Type 1 pseudohypoaldosteronism (PHA1) is a rare condition characterized by the resistance of the kidney to the effect of aldosterone. Secondary PHA1 is a syndrome that is most often related to urinary tract anomalies (UTAs) and/or urinary tract infections (UTIs). A similar pattern of electrolyte impairment is seen in congenital adrenal hyperplasia (CAH) and secondary PHA1, and CAH is a condition that requires urgent treatment. In our study, eight patients aged between 15 days and 8 months (seven males and one female) were included in the evaluation. It was aimed to evaluate cases of secondary PHA1 in our clinic and to identify the problems encountered in diagnosis and follow-up.

Methods. The records of the patients who presented to our hospital between February 2010 and 2021 were retrieved and retrospectively scanned.

Results. In all cases, hyponatremia, hyperkalemia, hyperaldosteronism, and hyperreninemia were detected. Other biochemical and hormonal tests were normal. Leukocytosis was detected in urine analysis, and urine cultures were productive. UTAs was detected in five cases. Nine episodes of PHA1 occurred in eight patients and fungal infections were responsible for causing two episodes. Four episodes of PHA1 needed mineralocorticoid treatment. On the third day, serum electrolytes normalized. Fludrocortisone treatment was continued for 1 week. In one case, UTIs were repeated with PHA1, but in the follow-up, there were no additional problems.

Conclusions. Secondary PHA1 should be kept in mind when hyponatremia and hyperkalemia are seen, especially in infants aged under 3 months or older, up to 8 months, who present with non-specific symptoms. Fungal infections should not be forgotten in UTI etiology because PHA1 episodes can be initiated. If CAH is suspected, mineralocorticoid treatment should be rapidly initiated.

Key words: fungal urinary infection, secondary pseudohypoaldosteronism, urinary tract anomaly, urinary tract infection.

Aldosterone plays a major role in the control of blood pressure through the control of sodium balance, fluid homeostasis, and transepithelial sodium transport.¹ The main effect of aldosterone in epithelial target tissues is to regulate sodium reabsorption, and potassium and hydrogen secretion. Aldosterone regulates this pathway through intracellular mineralocorticoid receptors (MR) and amiloride-sensitive epithelial sodium channels. Interruption of the intracellular MR signal pathway leads to the appearance of clinical signs of pseudohypoaldosteronism (PHA). Type 1 PHA (PHA1) is a rare condition characterized by the resistance of the kidney to the effect of aldosterone. In patients, metabolic acidosis associated with elevated plasma renin and aldosterone levels manifests with hyperkalemia and salt loss.² This rare syndrome starts in the neonatal period and early infancy and has two forms; (a) Genetic forms: There are two types, the renal form (autosomal dominant) and systemic form (autosomal recessive), (b) The secondary form of PHA1 which is limited to the kidney, most often related to urinary tract anomalies (UTAs) and/or urinary tract infections.
Secondary Pseudohypoaldosteronism

The Turkish Journal of Pediatrics ▪ May-June 2022

3. Secondary PHA1 is a problem that causes difficulties in diagnosis and treatment, which can be overlooked in early childhood and confronted with different causes.

A similar pattern of electrolyte impairment is seen in congenital adrenal hyperplasia (CAH) and PHA1 in infancy. CAH remains the most common cause and is a condition that requires urgent treatment. The incidence of the classic form of CAH is reported to range from 1:5000 to 1:15,000 and varies among ethnic/racial backgrounds. CAH is a group of autosomal recessive disorders encompassing enzyme deficiencies in the adrenal steroidogenesis pathway. Hyperpigmentation of skin creases and genitalia may be early signs of adrenal insufficiency. Depending on excessive androgen exposure, virilization findings occur in the external female genitalia; the external genitalia in males are usually unaffected, except for subtle penile enlargement. In CAH, low levels of aldosterone and cortisol, and elevated levels of renin, 17 hydroxyprogesterone (17 OHP), and adrenocorticotropic hormone (ACTH) are detected. The management of secondary PHA1 involves sodium supplementation and water replacement, ion exchange resins in cases of high potassium values, in some cases bicarbonate, antibiotics for UTIs, and surgical intervention for UTA when necessary. Stress-dose corticosteroids may be given to patients until the end of the hormone tests taken for differential diagnosis.

In this study, it was aimed to evaluate cases of secondary PHA1 in our clinic, and to identify the problems encountered in diagnosis and follow-up.

Material and Methods

The records of the patients who presented to our hospital between February 2010 and 2021 were retrieved and retrospectively scanned. The study protocol was approved by the Institutional Ethics Committee of Ankara University (approval number: 14-675-16). Informed consent was received from the parents of all patients included in the study.

Patients

Eight patients were included who were evaluated for hyperkalemia and hyponatremia. Hyperkalemia was accepted when the potassium level was ≥5.1 milliequivalents (mEq)/Liter (L) and hyponatremia, sodium level was <136 mEq/L. The bicarbonate level for acidosis was considered as <22 mEq/L, 17 OHP, cortisol, ACTH, plasma renin activity (PRA), and aldosterone levels were measured when hyponatremia and hyperkalemia were detected. Urinary system obstructions were evaluated using urinary ultrasonography (US) and voiding cystourethrography (VCUG). UTI was considered to be above five leukocytes/high-power field (hpf) in urine analysis microscopy and urine culture with a single pathogen greater than $10^5$ colonies (col)/milliliter (mL). Reproduction above $10^4$ col/mL was considered significant for fungal infections. Urine samples were taken using a urine catheter. Treatment with intravenous (IV) fluid and sodium replacement, IV antibiotics and/or antifungal agents was started. It was recorded whether glucocorticoids and/or mineralocorticoids were given.

Case Presentation

The clinical features and laboratory findings of the patients are shown in Tables I and II. On initial examination, all patients had hyperkalemia (6.9±1.0 mEq/L), hyponatremia (118.5±5.5 mEq/L), hyperaldosteronism (462.5±167.4 ng/dL), and hyperreninemia (116.6±67.6 ng/mL/hr). There was no history of parental consanguinity, no signs of atypical external genitalia, or hyperpigmentation in our cases.

Patient 1 was admitted to the emergency department due to weakness and the inability to feed orally. His physical examination showed decreased skin turgor and poor peripheral
circulation. A UTI was detected in a urine test. The patient was evaluated as having secondary PHA1 due to UTI. Hydrocortisone (single-dose) and fludrocortisone were added to antibiotic and IV sodium replacement therapy for possible surrenal insufficiency. Fludrocortisone was discontinued at the end of the first week when the 17 OHP result was normal.

Patient 2 presented with vomiting. His clinical examination showed dehydration. Antenatal US had shown bilateral hydronephrosis (HN). His laboratory findings suggested PHA1 secondary to UTI and UTA. He was treated first with IV saline. The IV fluconazole treatment was completed in 3 weeks.

Patient 3 was admitted with vomiting and irritability. Physical examination showed dehydration. Bilateral HN had been detected at the 31st week of gestation. On postnatal day 5, the patient was diagnosed as having a posterior urethral valve (PUV). At admission, he was considered to have secondary PHA1 associated with UTI and UTA. IV sodium replacement treatment for hyponatremia was started. IV fluconazole treatment was continued for 2 weeks. After the PUV resection surgery, when

Table I. Clinical features of patients.

| Patient | Sex | Age at admission | Birth weight/week | Type of urinary malformation | Surgical treatment | Urinalysis-Urine culture on admission |
|---------|-----|-----------------|-------------------|------------------------------|-------------------|--------------------------------------|
| 1       | Male| 3 months        | 1060 g/27 week    | -                            | -                 | 44 leucocyte/hpf-10^5 col/mL Klebsiella Pneumoniae |
| 2       | Male| 1.5 months      | 2350 g/34 week    | PUV                          | Stenosis excision at 2.5 months, Left nephroureterectomy and right ureteronephrostomy at 9.5 months | 234 leucocytes/hpf-10^5 col/mL Candida Glabrata |
| 3       | Male| 2.5 months      | 2980 g/35 week    | PUV                          | Stenosis excision at 3 months old | 885 leucocytes/hpf-8x10^5 col/mL Candida Albicans |
|         |     |                 |                   |                              |                   | 24 leucocytes/hpf-10^5 col/mL Klebsiella Pneumoniae |
| 4       | Girl| 2.5 months      | 2990 g/40 week    | Neurogenic bladder secondary to meningomyelocele | -                 | 219 leucocytes/hpf-10^5 col/mL Klebsiella Pneumoniae |
| 5       | Male| 6 months        | 3180 g/38 week    | Left UP stenosis              | Left pyeloplasty at 3.5 months old | 213 leucocytes/hpf-10^5 col/mL Enterobacter cloacae |
| 6       | Male| 8 months        | 2870 g/40 week    | -                            | -                 | 7 leucocytes/hpf-10^5 col/mL Escherichia coli |
| 7       | Male| 1.5 months      | 2950 g/38 week    | Double collecting system in the right kidney, Bilateral VUR | -                 | 259 leucocytes/hpf-10^5 col/mL Klebsiella Pneumoniae |
| 8       | Male| 15 days         | 3900 g/40 week    | PUV                          | -                 | 1746 leucocytes/hpf-10^5 col/mL Enterobacter Bugadensis |

UP: ureteropelvic, PUV: posterior urethral valve, hpf: high-power field
Table II. Laboratory features of the patients on admission and clinical follow-up.

| Patients     | BUN  | Cr  | Na  | K   | Cl  | pH  | HCO₃ | PRA  | Aldosterone | ACTH | Cortisol | 17 OHP | Treatment                                                                 |
|--------------|------|-----|-----|-----|-----|-----|------|------|-------------|------|----------|-------|---------------------------------------------------------------------------|
| Patient 1    | 15   | 0.09| 123 | 6   | 100 | 7.30| 17   | 277.6| 552         | 7.5  | 25.52    | 1.63  | IV antibiotic, IV fluid, Hydrocortisone (single-dose), Fludrocortisone (1 wk) |
| Day 3        | 136  | 4.1 |      |     |     |     |      |      |             |      |          |       |                                                                          |
| Day 14       |      |     |     |     |     |     |      | 1.27 | 0.81        | 50.01| 6.6       |       |                                                                          |
| Day 21       |      |     |     |     |     |     |      | 1.8  | 17          |      |           |       |                                                                          |
| Patient 2    | 41   | 0.40| 112 | 7.7 | 102 | 7.28| 12.5 | 121.6| 551         | 50.80| 39.52    | 2.65  | IV antibiotic + antifungal, IV fluid                                      |
| Day 3        | 13   | 0.50| 137 | 4.3 | 102 |     |      |      |             |      |          |       |                                                                          |
| Patient 3    | 52   | 0.66| 115 | 8.1 | 105 | 7.27| 13.2 | 97.7 | 242         | 11.36| 31.69    | 1.89  | IV antifungal, IV fluid                                                  |
| 1st PHA episode |      |     |     |     |     |     |      |      |             |      |          |       |                                                                          |
| Day 3        | 3    | 0.34| 137 | 5   |     |     |      |      |             |      |          |       |                                                                          |
| Day 14       |      |     |     |     |     |     |      | 1.1  | 16          | 45.05| 7.5       |       |                                                                          |
| 2nd PHA episode | 12   | 0.55| 123 | 6.8 |     |     |      | 97.7 | 480         | 5.07 | 30.81    | 1       | IV antibiotic, IV fluid                                                  |
| (2 mths later) |      |     |     |     |     |     |      |      |             |      |          |       |                                                                          |
| Day 2        | 138  | 4.9 |     |     |     |     |      |      |             |      |          |       |                                                                          |
| Day 14       |      |     |     |     |     |     |      | 30.6 | 187.9       |      |           |       |                                                                          |
| Day 28       |      |     |     |     |     |     |      | 1.9  | 17          |      |           |       |                                                                          |
| Patient 4    | 8    | 0.18| 128 | 5.2 | 99  | 7.33| 18   | 143.8| 497.8       | 7.7  | 7.71     | 2.33  | IV antibiotic, IV fluid                                                  |
| Day 3        | 136  | 4.2 |     |     |     |     |      |      |             |      |          |       |                                                                          |
| Day 21       |      |     |     |     |     |     |      | 0.92 | 15.5        |      |           |       |                                                                          |
| Patient 5    | 23   | 0.42| 119 | 6.2 | 101 | 7.28| 13   | 105  | 390         | 22.86| 6.25     | 2.55  | IV antibiotic, IV fluid                                                  |
| Day 2        | 2    | 0.17| 138 | 5.1 |     |     |      |      |             |      |          |       |                                                                          |
| Day 14       |      |     |     |     |     |     |      | 1.2  | 14.5        |      |           |       |                                                                          |
| Patient 6    | 6    | 0.24| 119 | 7.2 | 104 | 7.36| 20.6 | 86.3 | 300         | 7.9  | 60.60    | 1     | IV antibiotic, IV fluid, Hydrocortisone (single-dose), Fludrocortisone (1 wk) |
| Day 3        | 136  | 4   |     |     |     |     |      |      |             |      |          |       |                                                                          |
| Day 7        |      |     |     |     |     |     |      | 0.51 | 5.93        |      |           |       |                                                                          |

Normal Laboratory Values: BUN: 5-18 mg/dl, Creatinin (Cr): 0.32-0.6 mg/dl, Sodium (Na): 136-145 mEq/L, Potassium (K): 3.5-5.1 mEq/L, Clor (Cl): 98-108 mEq/L, Bicarbonate (HCO₃): 22-26 mEq/L, Plasma Renin Activity (PRA): 0.5-1.9 ng/mL/hr, Aldosterone: 0.8-17.2 ng/dL, Adrenocorticotropic hormone (ACTH): 7.2-63.3 pg/mL, Cortisol: <10 mcg/dL, 17 hydroxyprogesterone (17 OHP): <3 ng/mL.
he was aged 4.5 months, he underwent a second PHA1 episode after a UTI.

Patient 4 presented for evaluation routinely. Her history was characterized by the presence of meningomyelecele and flaccid paralysis of the lower extremities. Clean intermittent catheterization was performed since the 2nd month. Physical examination showed a meningomyelecele sac in the sacral region. She was accepted as having PHA1 due to UTI.

Patient 5 presented with vomiting. The physical examination was normal. Dilatation of the left renal collecting system had been detected during the antenatal period. Previous imaging studies revealed grade 4 ectasia and ureteropelvic (UP) stenosis on the left kidney using US. He was considered as having secondary PHA1 caused by obstructive uropathy and UTI.

Patient 6 was admitted to the emergency department due to lethargy and decreased oral acceptance. His physical examination showed dehydration and circulatory collapse. A urine microscopy examination revealed UTI. He was accepted as having PHA1 due to UTI. Corticosteroids were added to the therapy for possible surrenal insufficiency. Fludrocortisone was discontinued at the end of the first week.

Patient 7 presented with vomiting and oral intolerance. He had dehydration and pallor and did not look well. In his abdominal US, a double collecting system was detected on the right kidney and grade 2 dilatation on the left kidney. Bilateral grade 5 vesicoureteral reflux (VUR) was observed in VCUG. UTI was detected in a urine test. He was considered to have secondary PHA1 caused by UTA and UTI. Hydrocortisone (single-dose) and fludrocortisone were started. CAH was excluded when the 17 OHP level was normal.

Patient 8 presented to the emergency department with a one-week history of poor feeding, vomiting, and lethargy. Urine microscopic examination revealed UTI. Antenatal US had shown bilateral HN and PUV was detected in the postnatal period. He was accepted as having
Secondary Pseudohypoaldosteronism

The Turkish Journal of Pediatrics ▪ May-June 2022

PHA1 due to UTI and UTA. Corticosteroids were added to the therapy. Mineralocorticoid therapy was discontinued at the end of the first week.

Among our patients, males were in the majority (87.5%, 7/8) and 62.5% (5/8) were in the under 3 months age group. Although UTI was present in eight of our patients, there was no underlying UTA in two of these patients; one patient had a neurogenic bladder secondary to meningomyelocele. UTA and UTI were observed in 62.5% (5/8) of our patients. All patients recovered from their electrolyte imbalances on the third day of hospitalization with antibiotic and/or antifungal treatment for underlying infections and intravenous saline. Hydrocortisone (single-dose) and fludrocortisone were added to the therapy for possible surrenal insufficiency in Patient 1, Patient 6, Patient 7, and Patient 8.

Discussion

Secondary PHA1 is due to transient aldosterone resistance and has been described in infants with urinary tract malformations or UTIs or both. Searching MEDLINE, we found 137 cases of transient PHA1 since 1983. Most of the reported cases by sex were male 70.5% (91/129, 1:1.41), and 84.6% (116/137, 1:1.18) were in the under 3 months age group. In our study, male sex was more prevalent, on the other hand, the age group under 3 months was found to be lower than in the literature.

In the literature, UTI was present in 125 of 137 patients (91.1%), UTA and UTI were seen together in 87.2% (109/125) of cases. UTA and UTI were observed in 62.5% of our cases. Uncircumcised male infants aged under 3 months have the highest baseline prevalence of UTI and the incidence of obstructive uropathy is higher in males than females. The risk of severe electrolyte imbalance in children with obstructive uropathy is significantly reduced after 3 months and this age-related condition seems to be related to immaturity in kidney tubules. We believe that the frequency of PHA1 is higher in boys aged under 3 months for these reasons. Although the true prevalence of PHA1 associated with UTI and/or UTA is not known, it may be higher than reflected in the published literature because ascertainment is dependent on physician awareness.

The underlying pathogenesis of secondary PHA1 is unclear. Possible mechanisms include the emergence of bacterial endotoxin damage at the aldosterone receptors secondary to cytokines such as transforming growth factor-β (TGF-β), and parenchymal scarring secondary to obstruction. Urinary tract obstruction increases the intrarenal synthesis of many cytokines, such as interleukin (IL)-1, IL-6, tumor growth factor (TGF)-β1, and tumor necrosis factor alfa (TNF-α). TGF-β1 is produced from infiltrated macrophages and renal tubule cells and suppresses the effect of aldosterone by reducing MR susceptibility.

Severe hyponatremia, hyperkalemia, and dehydration may be seen with CAH, isolated aldosterone deficiency, and other forms of hypoadrenalism, or PHA. The most common cause of hypoaldosteronism is adrenal failure, which is usually caused by CAH during early life. Treatment should begin as soon as possible for the possibility of adrenal insufficiency. If CAH is excluded, hydrocortisone is stopped. In cases of hyponatremia and hyperkalemia, the key finding of elevated serum aldosterone and renin level strongly suggests the diagnosis of PHA1. Two forms of PHA1 can be distinguished at the clinical and genetic level. Family history, laboratory studies, and the presence of urinary tract malformations and/or UTI may help to differentiate genetic PHA1 from secondary PHA1. The sweat test helps when considering the genetic form; if the sweat test result is normal, the renal form should be considered, and if it is high, the systemic form should be considered (Fig. 1).

In our cases, Candida spp. appeared as the causative agent of two PHA1 episodes. Candida infections were
the most important causes of clinically proven UTI in our patients, who produced no other uropathogens. Initially, IV antibiotic therapy was started for the patients but there was no reproduction in the first urine culture and IV fluconazole treatment was added to two urine cultures in the presence of the same amount of Candida spp. In our patients, the causes of susceptibility to Candida-related UTIs appeared to be congenital and structural abnormalities of the urinary tract and urinary stasis. It may also be another important risk factor for premature birth history in both patients. Although obstruction and/or urinary tract stones have been identified for renal involvement, the mechanism of settlement and proliferation in the calyx has not been fully elucidated. Further studies are needed on how UTIs due to Candida species lead to secondary PHA1.

These case series show the need for testing for UTIs in afebrile infants with non-specific symptoms such as vomiting and agitation.
Secondary Pseudohypoaldosteronism

Secondary pseudohypoaldosteronism (PHA1) is a rare disorder characterized by aldosterone resistance, typically associated with electrolyte imbalances. It is crucial to consider PHA1 as a differential diagnosis when co-existent with hyponatremia and hyperkalemia, especially in male infants when secondary PHA1 is suspected. Renal US supports the diagnosis of secondary PHA1. Our patients also demonstrated the transient nature of the aldosterone resistance; therefore, genetic analysis was not performed.

It is controversial in the literature that the most important risk factor leading to aldosterone resistance is UTA or UTI. With younger age, the risk for secondary PHA1 increases, and severe electrolyte imbalance significantly increases in patients with obstructive uropathy. Preterm birth history also facilitates the development of PHA1 by increasing kidney immaturity.

In patient 1, UTI, prematurity, and age 3 months were the most important risk factors as the secondary cause of PHA1. Patient 2 and patient 3 were found to have UTA, UTI, prematurity, and age under 3 months. Patient 3 underwent PUV resection surgery in the third month after the first PHA1 attack. However, this patient had PHA1 for the second time after UTI at 4.5 months. The ongoing bilateral grade 3-4 VUR appears to be the cause of the second attack. Possible risk factors for PHA1 in patient 4 are clear intermittent catheterization, UTI, and age under 3 months. Patient 5 underwent surgery at the age of 3.5 months due to left UP stenosis. At the age of 6 months, patient 5 had PHA1 as a consequence of ongoing grade 3-4 HN and UTI. In patient 6, UTI was found to be the only secondary cause of PHA1. UTA, UTI, and age less than 3 months in patient 7 and patient 8 were possible risk factors.

The management of secondary PHA1 involves sodium supplementation and water replacement, ion exchange resins when there are high potassium values, bicarbonate in some cases, antibiotics for UTIs, and surgical intervention for UTA when necessary. The abnormalities quickly disappear after medical or surgical therapy. In our study, all patients recovered from their electrolyte imbalances on the third day of hospitalization with antibiotic and/or antifungal treatment for underlying infections and intravenous saline. In patient 1 and patient 5, PRA and aldosterone levels normalized at 2 weeks. Despite the underlying PUV in patient 2, PRA and aldosterone post-UTI normalized at 2 weeks. On the other hand, although patient 8 was given antibiotic treatment for UTI, aldosterone levels did not normalize at 4 weeks. This situation may be related to the ongoing PUV. In the first PHA episode in patient 3, PRA and aldosterone levels were normalized at 2 weeks in combination with UTI and PUV, whereas in the second PHA episode caused by UTI alone, the improvement was observed at 4 weeks. Single-dose hydrocortisone and fludrocortisone treatment were given to patient 1, 6, 7, and 8 for the possibility of CAH due to poor hemodynamic circulatory findings and biochemical profiles. Glucocorticoid and mineralocorticoid treatment were started without waiting for hormone test results (cortisol, aldosterone, 17 OHP). In the literature, there are cases in which glucocorticoid and mineralocorticoid treatment were initiated and these therapies were discontinued during follow-up. In our study, fludrocortisone was discontinued at the end of the first week when the 17 OHP result was normal.

In patients presenting with non-specific symptoms during early infancy, when hyperkalemia and hyponatremia in biochemical parameters are noticed, CAH or adrenal insufficiency and secondary PHA1 should be considered. Urine analysis, urine culture, and renal US imaging are very important in terms of rapid identification, especially in children younger than 3 months or older, up to 8 months. If a pathologic condition is detected in these studies, PHA1 should first come to mind. Fungal infections should not be forgotten in the etiology of UTI because PHA1 episodes can be initiated.
Ethical approval

Ankara University Ethics committee approval for the study was received. (approval number: 14-675-16).

Author contribution

The authors confirm contribution to the paper as follows: study conception and design: MB, FG; data collection: FG; analysis and interpretation of results: MB, ZŞ, FG; draft manuscript preparation: ZŞ, FG. All authors reviewed the results and approved the final version of the manuscript.

Source of funding

The authors declare the study received no funding.

Conflict of interest

The authors declare that there is no conflict of interest.

REFERENCES

1. Pearce D, Bhargava A, Cole TJ. Aldosterone: its receptor, target genes and actions. Vitam Horm 2003; 66: 29-76. https://doi.org/10.1016/S0083-6729(03)01002-1
2. Kuhnle U. Pseudohypoaldosteronism: mutation found, problem solved?. Mol Cell Endocrinol 1997; 133: 77-80. https://doi.org/10.1016/S0303-7207(97)00149-4
3. Belot A, Ranchin B, Fitchner C, et al. Pseudohypoaldosteronisms, report on a 10-patient series. Nephrol Dial Transplant 2008; 23: 1636-1641. https://doi.org/10.1093/ndt/gfm862
4. Bogdanovic R, Stajic N, Putnik J, Paripovic A. Transient type I pseudo-hypo aldosteronism: report on an eight-patient series and literature review. Pediatr Nephrol 2009; 24: 2167-2175. https://doi.org/10.1007/s00467-009-1285-8
5. Thil’en A, Nordenström A, Hagenfeldt L, von Döbeln U, Guthenberg C, Larson A. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics 1998; 101: E11. https://doi.org/10.1542/peds.101.4.e11
6. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet 2017; 390: 2194-2210. https://doi.org/10.1016/S0140-6736(17)31431-9
7. Manikam L, Cornes MP, Kalra D, Ford C, Gama R. Transient pseudohypoaldosteronism masquerading as congenital adrenal hyperplasia. Ann Clin Biochem 2011; 48: 380-382. https://doi.org/10.1258/abc.2011.010264
8. Schoen EJ, Bhatia S, Ray GT, Clapp W, To TT. Transient pseudohypoaldosteronism with hyponatremia-hyperkalemia in infant urinary tract infection. J Urol 2002; 167: 680-682. https://doi.org/10.1016/S0022-5347(01)69124-9
9. Nandagopal R, Vaidyanathan P, Kaplowitz P. Transient pseudohypoaldosteronism due to urinary tract infection in infancy: a report of 4 cases. Int J Pediatr Endocrinol 2009; 2009: 195728. https://doi.org/10.1186/1687-9856-2009-195728
10. Rogers D. Final diagnosis: transient pseudohypoaldosteronism (TPH) caused by UTI without concordant obstructive uropathy. Clin Pediatr (Phila) 2008; 47: 405-408.
11. Torun-Bayram M, Soylu A, Kasap-Demir B, Alavgut D, Turkmen M, Kavukçu S. Secondary pseudohypoaldosteronism caused by urinary tract infection associated with urinary tract anomalies: case reports. Turk J Pediatr 2012; 54: 67-70. PMID: 22397047.
12. Kibe T, Sobajima T, Yoshimura A, Uno Y, Wada N, Ueta I. Secondary pseudohypoaldosteronism causing cardiopulmonary arrest and cholelithiasis. Pediatr Int 2014; 56: 270-272. https://doi.org/10.1111/ped.12267
13. Ruiz Gines MA, Ruiz Gines JA, Saura Montalban J, Fontelles Alcover R, Piqueras Martinez AN. Pseudohypoaldosteronism type 1 secondary to vesicoureteral reflux: An endocrinologic emergency. Endocrinol Nutr 2014; 61: 495-497. https://doi.org/10.1016/j.endoen.2014.05.004
14. Abraham MB, Larkins N, Choong CS, Shetty VB. Transient pseudohypoaldosteronism in infancy secondary to urinary tract infection. J Paediatr Child Health 2017; 53: 458-463. https://doi.org/10.1111/jpc.13481
15. Atmis B, Turan I, Melek E, Karabay Bayazit A. An infant with hyponatremia, hyperkalemia, and metabolic acidosis associated with urinary tract infection: Questions. Pediatr Nephrol 2019; 34: 1737. https://doi.org/10.1007/s00467-019-04252-4
16. Korkut S, Akin L, Hatipoglu N, et al. A potential serious complication in infants with congenital obstructive uropathy: secondary pseudohypoaldosteronism. J Pak Med Assoc 2019; 69: 108-112. PMID: 30623923.
17. Delforme X, Kongolo G, Cauliez A, Braun K, Haraux E, Bucksin P. Transient pseudohypoaldosteronism: a potentially severe condition affecting infants with urinary tract malformation. J Pediatr Urol 2019; 15: 265.e1-265.e7. https://doi.org/10.1016/j.jpuro.2019.03.002

18. Günay N, Kucukaydin Z, Pinarbas S, Dursun İ, Duşünsel R. Transient pseudohypoaldosteronism. Paediatr Int Child Health 2019; 39: 154. https://doi.org/10.1080/20469047.2018.1439433

19. De Clerck M, Walle JV, Dhont E, Dehoorne J, Keenswijk W. An infant presenting with failure to thrive and hyperkalemia owing to transient pseudohypoaldosteronism: case report. Paediatr Int Child Health 2018; 38: 277-280. https://doi.org/10.1080/20469047.2017.1329889

20. Xu M, Di Blasi C, Dickerson J, Jack R, Rutledge JC. A 5-week-old boy with failure to thrive, marked hyperkalemia, and hyponatremia. Clin Chem 2016; 62: 1439-1443. https://doi.org/10.1037/clinche.2015.252320

21. Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J 2008; 27: 302-308. https://doi.org/10.1097/INF.0b013e3181e4122

22. Melzi ML, Guez S, Sersale G, et al. Acute pyelonephritis as a cause of hyponatremia/hyperkalemia in young infants with urinary tract malformations. Pediatr Infect Dis J 1995; 14: 56-59. https://doi.org/10.1097/00006454-199501000-00012

23. Watanabe T. Reversible secondary pseudohypoaldosteronism. Pediatr Nephrol 2003; 18: 486. https://doi.org/10.1007/s00467-003-1104-6

24. Klahr S. Obstructive nephropathy. Intern Med 2000; 39: 355-361. https://doi.org/10.2169/internalmedicine.39.355

25. Furness PD, Maizels M, Han SW, Cohn RA, Cheng EY. Elevated bladder urine concentration of transforming growth factor-beta1 correlates with upper urinary tract obstruction in children. J Urol 1999; 162: 1033-1036. https://doi.org/10.1016/S0022-5347(01)68056-X

26. Fischer JF, Chew WH, Shadomy S, Duma RJ, Mayhall CG, House WC. Urinary tract infections due to Candida Albicans. Rev Infect Dis 1982; 4: 1107-1118. https://doi.org/10.1093/clinids/4.6.1107

27. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345: 1660-1666. https://doi.org/10.1056/NEJMoa010494

28. Kauffman CA. Candiduria. Clin Infect Dis 2005; 41(Suppl 6): 371-376. https://doi.org/10.1086/430918

29. Thies KC, Boos K, Muller-Deile K, Ohrdorf W, Beushausen T, Townsend P. Ventricular flutter in a neonate-severe electrolyte imbalance caused by urinary tract infection in the presence of urinary tract malformation. J Emerg Med 2000; 18: 47-50. https://doi.org/10.1016/S0736-4679(99)00161-4

30. Holtback U, Aperia AC. Molecular determinants of sodium and water balance during early human development. Semin Neonatol 2003; 8: 291-299. https://doi.org/10.1016/S1084-2756(03)00042-3

31. Parisi G, Rojo S, De Pascale S, et al. Transient pseudohypoaldosteronism secondary to congenital malformation pathology of the urinary tract (valves of the posterior urethra): a report of a case with elements of a physiopathological nature. Pediatr Med Chir 1998; 20: 289-293. PMID: 9866855.